Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2017-10-24 Director's Dealing
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document text is titled "Mandatory notification of trade" and explicitly states that the CEO, Christian Jørgensen, purchased shares of the company. This directly relates to reporting personal share transactions by company directors or executives (insider trades). This aligns perfectly with the definition for Director's Dealing (DIRS). The document length is very short (566 chars), but the content is a direct notification of a trade, not an announcement about a report, making DIRS the most specific fit over RNS.
2017-10-24 English
Woulgan® to be listed on UK Drug Tariff
Regulatory Filings Classification · 95% confidence The document is a short press release announcing that the product Woulgan will be listed on the UK Drug Tariff starting January 2018. This is a specific business update related to market access and product commercialization, but it does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is not a management change (MANG), director dealing (DIRS), dividend notice (DIV), or a formal legal proceeding (LTR). Since it is a specific announcement about market access and commercial strategy, and it is not a general regulatory filing fallback (RNS), it is best classified as a general business update. Given the provided definitions, the closest fit for a specific, non-financial, non-governance business milestone announcement that doesn't fit elsewhere is often categorized under Regulatory Filings (RNS) if it's a general announcement, or potentially a Capital/Financing Update (CAP) if it implies revenue impact, but this is purely commercial access. Since it is a specific, non-standard announcement, RNS (Regulatory Filings) serves as the most appropriate general regulatory/announcement category when a more specific business event code is missing. However, upon re-evaluation against the provided list, this is a significant commercial/market update. It is not a proxy, not a dividend, not an earnings release, not a management change. It is a specific business development announcement. Given the options, RNS is the catch-all for regulatory/official announcements that don't fit elsewhere. The document length is short (1460 chars), suggesting it's an announcement rather than a full report.
2017-10-19 English
Woulgan® to be listed on UK Drug Tariff
Regulatory Filings Classification · 100% confidence The document is a short press release dated October 19, 2017, announcing that the product Woulgan® will be listed on the UK Drug Tariff starting January 2018. This is a specific business update regarding market access and product strategy, not a comprehensive financial report (like 10-K or IR), a formal regulatory filing (like DIRS or MRQ), or a transcript. It fits best under a general regulatory or business announcement category. Since it is not a dividend notice, management change, or financing event, and it is a specific announcement, the most appropriate general category is Regulatory Filings (RNS), as it serves as a general regulatory/market access update that doesn't fit the more specific codes. Given the very short length and announcement nature, RNS is the best fit among the available options for a non-financial, non-governance specific update.
2017-10-19 English
Biotec Pharmacon: Results for Q3 2017
Earnings Release Classification · 98% confidence The document explicitly reports key financial figures for a specific period ("Results for Q3 2017"), including sales (NOK 14.4 million) and EBITDA (NOK -7.3 million). It discusses business segments (Woulgan®, ArcticZymes) and provides management commentary. Crucially, it states, "The complete interim report for Q3 2017 is enclosed." This structure—a summary of quarterly results with a reference to the full report—is characteristic of an Earnings Release (ER). Although it mentions the full report, the document itself contains the core earnings highlights, making ER the most appropriate classification over RPA, especially given the substantial content summarizing the quarter's performance. The document is not the comprehensive 'Interim Report' (IR) itself, but the initial announcement of those results. Q3 2017
2017-10-19 English
Biotec Pharmacon: Q3 2017 Presentation
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 2017 Presentation' and contains detailed financial tables (Income Statement, Cash Flow, Segmental Analysis) for the third quarter of 2017. It provides a comprehensive review of business activities, segment performance (Beta-glucans, ArcticZymes), and outlook. Since it contains substantive financial data and analysis for a specific interim period (Q3), it is classified as an Interim/Quarterly Report. Q3 2017
2017-10-19 English
Biotec Pharmacon: Q3 2017 Presentation
Report Publication Announcement Classification · 98% confidence The document text is very short (492 characters) and explicitly states that the 'Q3 2017 Presentation' is 'attached' and also available via webcast. This structure—announcing the availability of presentation materials for a specific period (Q3 2017)—fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than being the full presentation itself (which would likely be classified as IP or ER/IR if it contained the full financial details). Since it is an announcement about a presentation being available, RPA is the most appropriate code based on the 'MENU VS MEAL' rule.
2017-10-19 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.